Drug Profile


Alternative Names: ALLOD-2H; ALLOD2; ATNC 05

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Allodynic Therapeutics
  • Class Analgesics; Antimigraines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Migraine
  • Phase II Back pain

Most Recent Events

  • 18 Feb 2017 Phase-II/III clinical trials in Migraine in USA (PO) (NCT03061734)
  • 19 Apr 2016 Phase-II development for Back pain is ongoing in USA (PO)
  • 31 Mar 2014 Allodynic Therapeutics terminates phase II/III trial prior to enrolment in orofacial Neuropathic pain in the USA (NCT01920087)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top